Drug intelligence / Profile preview

beclometasone + budesonide + fluticasone propionate

Development stage
Discontinued
Lead developer
AstraZeneca
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Inhalation, Intranasal, Oral, Rectal
01

Overview

This is a combination of three inhaled corticosteroids—beclometasone, budesonide, and fluticasone propionate. Each component is a synthetic glucocorticoid used primarily for the management and control of asthma and other inflammatory airway diseases. These drugs act by binding to the glucocorticoid receptor, leading to anti-inflammatory effects in the airways, reducing symptoms such as wheezing and shortness of breath. While each drug individually is widely used in clinical practice for asthma control, there are no known marketed products or clinical guidelines supporting their use together as a triple combination in a single formulation. The mechanism of action for all three involves suppression of airway inflammation through inhibition of multiple types of inflammatory cells (e.g., eosinophils) and mediators.

Brand names
Flovent DiskusQVARPulmicort Flexhaler
Other names
fluticasone propionatebeclomethasone dipropionatebudesonide
02

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on beclometasone + budesonide + fluticasone propionate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on beclometasone + budesonide + fluticasone propionate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call